Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced the full launch of Axoguard HA+ Nerve
Protector.
“Axoguard HA+ is an important extension of our nerve protection
platform,” commented Karen Zaderej, Axogen's Chairman, CEO, and
President. “The release of Axoguard HA+ expands opportunities for
surgeons to treat a wider range of nerve protection
challenges.”
Axoguard HA+ Nerve Protector is a proprietary nerve protection
device uniquely designed to provide both short- and long-term
protection for peripheral nerve injuries. The device is comprised
of a processed porcine submucosa extracellular matrix base layer
with a hyaluronate-alginate gel coating. The gel layer facilitates
enhanced nerve gliding to aid in minimizing soft tissue
attachments, while the base layer is remodeled into a long-term
protective tissue layer.
The nerve protection category covers a wide range of injuries
and defects, including nerve compression, crush, and complex
traumatic injuries. The diversity of these injury types and their
anatomical locations present unique challenges for both the surgeon
and the patient. Optimizing outcomes requires targeted solutions to
adequately address the nerve and the surrounding environment
throughout the healing process.
“Axoguard HA+ has the potential to greatly impact patients who
suffer from compression nerve injuries, particularly where the
injury is in proximity to high mobility joints,” noted Dr. Peter J.
Evans, MD, PhD, Division Chair, Orthopedics Surgery, Cleveland
Clinic Florida Region. “The increased gliding feature and
optimized handling of Axoguard HA+ Nerve Protector allows surgeons
to address the challenges of these injury types during the early
and most critical phases of healing.”
About Axogen
Axogen (AXGN) is the leading Company focused
specifically on the science, development, and commercialization of
technologies for peripheral nerve regeneration and repair. Axogen
employees are passionate about helping to restore peripheral nerve
function and quality of life to patients with physical damage or
transection to peripheral nerves by providing innovative,
clinically proven, and economically effective repair solutions for
surgeons and health care providers. Peripheral nerves provide the
pathways for both motor and sensory signals throughout the body.
Every day, people suffer traumatic injuries or undergo surgical
procedures that impact the function of their peripheral nerves.
Physical damage to a peripheral nerve, or the inability to properly
reconnect peripheral nerves, can result in the loss of muscle or
organ function, the loss of sensory feeling, or the initiation of
pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products that are used across
two primary application categories: scheduled, non-trauma
procedures and emergent trauma procedures. Scheduled procedures are
generally characterized as those where a patient is seeking relief
from conditions caused by a nerve defect or surgical procedure.
These procedures include providing sensation for women seeking
breast reconstruction following a mastectomy, nerve reconstruction
following the surgical removal of painful neuromas, oral and
maxillofacial procedures, and nerve decompression. Emergent
procedures are generally characterized as procedures resulting from
injuries that initially present in an ER. These procedures are
typically referred to and completed by a specialist either
immediately or within a few days following the initial injury.
Axogen’s product portfolio includes Avance®
Nerve Graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa ECM coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; Axoguard
HA+ Nerve Protector™, a porcine submucosa ECM base layer coated
with a proprietary hyaluronate-alginate gel, a next-generation
technology designed to provide short- and long-term protection for
peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine
submucosa ECM product used to protect a peripheral nerve end and
separate the nerve from the surrounding environment to reduce the
development of symptomatic or painful neuroma. The Axogen portfolio
of products is available in the United States, Canada, Germany, the
United Kingdom, Spain, South Korea, and several other
countries.
Cautionary Statements Concerning
Forward-Looking Statements
This press release contains “forward-looking”
statements as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current
expectations or predictions of future conditions, events, or
results based on various assumptions and management's estimates of
trends and economic factors in the markets in which we are active,
as well as our business plans. Words such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” “projects,” “forecasts,” “continue,” “may,” “should,”
“will,” “goals,” and variations of such words and similar
expressions are intended to identify such forward-looking
statements. Actual results or events could differ materially from
those described in any forward-looking statements as a result of
various factors, including, without limitation, statements related
to the continued impact of COVID-19, global supply chain issues,
record inflation, hospital staffing issues, product development,
product potential, expected clinical enrollment timing and
outcomes, regulatory process and approvals, APC renovation timing
and expense, financial performance, sales growth, surgeon and
product adoption, market awareness of our products, data
validation, our visibility at and sponsorship of conferences and
educational events, global business disruption caused by Russia’s
invasion of Ukraine and related sanctions, as well as those risk
factors described under Part I, Item 1A., “Risk Factors,” of our
Annual Report on Form 10-K for the most recently ended fiscal year.
Forward-looking statements are not a guarantee of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made and, except as required by applicable
law, we assume no responsibility to publicly update or revise any
forward-looking statements.
Contact:Axogen,
Inc.InvestorRelations@axogeninc.com
Media Inquiries:Ignacio
Guerrero-Ross, Ph.D.Russo
Partners646.942.5604ignacio.guerrero-ros@russopartnersllc.com
Grafico Azioni Axogen (NASDAQ:AXGN)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Axogen (NASDAQ:AXGN)
Storico
Da Giu 2023 a Giu 2024